Methocarbamol and Tagamet drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Methocarbamol (methocarbamol) and Tagamet (cimetidine). Common drug interactions include renal failure among females and chronic kidney disease among males.

The phase IV clinical study analyzes what interactions people have when they take Methocarbamol and Tagamet. It is created by eHealthMe based on reports of 40 people who take the same drugs from the FDA, and is updated regularly.

What is Methocarbamol?

Methocarbamol has active ingredients of methocarbamol. It is often used in muscle spasms. eHealthMe is studying from 17,766 Methocarbamol users. Check the latest studies of Methocarbamol.

What is Tagamet?

Tagamet has active ingredients of cimetidine. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 9,011 Tagamet users. Check the latest studies of Tagamet.



On Jul, 12, 2026

40 people who take Methocarbamol and Tagamet together, and have interactions are studied.

Methocarbamol and Tagamet drug interactions.

What are the common drug interactions of Methocarbamol and Tagamet, by gender? *:

female:

  1. Renal failure (kidney dysfunction)
  2. Depression
  3. Anxiety
  4. Bone disorder
  5. Fall
  6. Osteoporosis (bones weak and more likely to break)
  7. Nephrogenic anaemia (anaemia due to kidney disease)
  8. Suicidal ideation
  9. Arthralgia (joint pain)
  10. Arthritis (form of joint disorder that involves inflammation of one or more joints)

male:

  1. Chronic kidney disease
  2. Renal failure (kidney dysfunction)
  3. Tubulointerstitial nephritis (a form of nephritis affecting the interstitium of the kidneys surrounding the tubules)
  4. Glomerulonephritis minimal lesion (a disease of the kidney that causes nephrotic syndrome and usually affects children)
  5. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  6. Nephrogenic anaemia (anaemia due to kidney disease)
  7. Death
  8. Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
  9. Metabolic encephalopathy (disorder or disease of the brain due to the body's disability to use energy)

What are the common drug interactions of Methocarbamol and Tagamet, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Fall
  2. Foot fracture
  3. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  4. Nephrogenic anaemia (anaemia due to kidney disease)
  5. Osteoarthritis (a joint disease caused by cartilage loss in a joint)
  6. Osteoporosis (bones weak and more likely to break)
  7. Pyrexia (fever)
  8. Renal failure (kidney dysfunction)
  9. Spinal fracture (fracture in one of vertebrae)
  10. Thoracic vertebral fracture

40-49:

  1. Renal failure (kidney dysfunction)
  2. Anxiety
  3. Chronic kidney disease
  4. Depression
  5. Suicidal ideation
  6. Bipolar i disorder (mood disorder that is characterized by at least one manic or mixed episode)
  7. Nephrogenic anaemia (anaemia due to kidney disease)
  8. Renal injury (kidney injury)
  9. Drug abuse
  10. Mania (a state of abnormally elevated or irritable mood)

50-59:

  1. Chronic kidney disease
  2. Renal failure (kidney dysfunction)
  3. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  4. Nephrogenic anaemia (anaemia due to kidney disease)
  5. Fall
  6. Abnormal behaviour
  7. Anxiety
  8. Arthralgia (joint pain)
  9. Arthritis (form of joint disorder that involves inflammation of one or more joints)
  10. Balance disorder

60+:

  1. Chronic kidney disease
  2. Glomerulonephritis minimal lesion (a disease of the kidney that causes nephrotic syndrome and usually affects children)
  3. Cardiovascular disorder (heart diseases)
  4. Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
  5. Coronary artery disease (plaque building up along the inner walls of the arteries of the heart, which narrows the arteries and restricts blood flow to the heart)
  6. Depression
  7. Foot fracture
  8. Liver injury
  9. Lumbar radiculopathy (radicular pain in the low back and legs)
  10. Multiple fractures

What are the existing conditions these people have? *

  1. Pain: 22 people, 55.00%
  2. High Blood Cholesterol: 17 people, 42.50%
  3. High Blood Pressure: 16 people, 40.00%
  4. Depression: 16 people, 40.00%
  5. Stress And Anxiety: 11 people, 27.50%
  6. Infection: 11 people, 27.50%
  7. Neuralgia (pain in one or more nerves): 10 people, 25.00%
  8. Fluid Retention (an abnormal accumulation of fluid in the blood): 9 people, 22.50%
  9. Headache (pain in head): 8 people, 20.00%
  10. Nausea (feeling of having an urge to vomit): 7 people, 17.50%

* Approximation only. Some reports may have incomplete information.

Do you take Methocarbamol and Tagamet?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Methocarbamol and Tagamet:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Methocarbamol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Tagamet:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Methocarbamol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tagamet and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on methocarbamol and cimetidine (the active ingredients of Methocarbamol and Tagamet, respectively), and Methocarbamol and Tagamet (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: